FIELD: biotechnology.
SUBSTANCE: group of inventions is described including a stable aqueous composition based on an antibody, a set that differ in that it is a sealed container comprising a composition based on an antibody, a dosage form suitable for parenteral injection to a human, a pre-filled syringe, a method for preparing a stable aqueous composition based on an antibody, a method for the treatment of a lung disease or disorder in a patient. In one embodiment, a stable aqueous composition based on an antibody contains from approximately 2 mg/ml to approximately 100 mg/ml of an antibody, where the antibody contains a variable region of a heavy chain containing CDR1, CDR2 and CDR3 with SEQ ID NO: 5-7, and a variable region of a light chain containing CDR1, CDR2 and CDR3 with SEQ ID NO: 8-10 and polysorbate-20.
EFFECT: invention expands the arsenal of stable antibody compositions.
19 cl, 22 dwg, 7 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES TO C5 | 2018 |
|
RU2787595C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| COMPOSITIONS OF ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2772781C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS | 2015 |
|
RU2757961C2 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| LOX1-SPECIFIC BINDING PROTEINS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764993C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
